These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18301060)

  • 41. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
    Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
    Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
    Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
    Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.
    Potter M; Odueyungbo A; Yang H; Saeed S; Klein MB;
    AIDS; 2010 Jul; 24(12):1857-65. PubMed ID: 20479633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.
    Baker JV; Peng G; Rapkin J; Abrams DI; Silverberg MJ; MacArthur RD; Cavert WP; Henry WK; Neaton JD;
    AIDS; 2008 Apr; 22(7):841-8. PubMed ID: 18427202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.
    Sereti I; Gulick RM; Krishnan S; Migueles SA; Palfreeman A; Touzeau-Römer V; Belloso WH; Emery S; Law MG;
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):456-462. PubMed ID: 31241541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome.
    Brigido L; Rodrigues R; Casseb J; Custodio RM; Fonseca LA; Sanchez M; Duarte AJ
    AIDS Patient Care STDS; 2004 Apr; 18(4):189-98. PubMed ID: 15142349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration.
    Jaroszewicz J; Wiercinska-Drapalo A; Lapinski TW; Prokopowicz D; Rogalska M; Parfieniuk A
    Antivir Ther; 2006; 11(5):641-5. PubMed ID: 16964834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.
    Lange CG; Lederman MM; Madero JS; Medvik K; Asaad R; Pacheko C; Carranza C; Valdez H
    J Acquir Immune Defic Syndr; 2002 May; 30(1):33-40. PubMed ID: 12048361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.
    Vaamonde CM; Hoover DR; Anastos K; Tan T; Shi Q; Gao W; Kovacs A; Cohen M; DeHovitz J; Glesby MJ
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):222-31. PubMed ID: 16545008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.
    Ostrowski SR; Katzenstein TL; Thim PT; Pedersen BK; Gerstoft J; Ullum H
    J Infect Dis; 2005 Feb; 191(3):348-57. PubMed ID: 15633093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determinants of suboptimal CD4
    Handoko R; Colby DJ; Kroon E; Sacdalan C; de Souza M; Pinyakorn S; Prueksakaew P; Munkong C; Ubolyam S; Akapirat S; Chiarella J; Krebs S; Sereti I; Valcour V; Paul R; Michael NL; Phanuphak N; Ananworanich J; Spudich S;
    J Int AIDS Soc; 2020 Sep; 23(9):e25585. PubMed ID: 32949118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
    Pai NP; Lawrence J; Reingold AL; Tulsky JP
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006148. PubMed ID: 16856117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
    Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.
    Chirouze C; Journot V; Le Moing V; Raffi F; Piroth L; Reigadas S; Cassuto JP; Chêne G; Leport C; Hoen B;
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):204-8. PubMed ID: 25590273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of persistent moderate viremia on disease progression during HIV therapy.
    Raffanti SP; Fusco JS; Sherrill BH; Hansen NI; Justice AC; D'Aquila R; Mangialardi WJ; Fusco GP;
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1147-54. PubMed ID: 15319674
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
    Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
    AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.